Prohibiting Adversarial Patents Act of 2026

Issues related to intellectual property legislation and regulation; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecting Our Courts from Foreign Manipulation Act; H.R. 7015, Protecting TPLF From Abuse Act

Client expense: Not reported · Firm income: $70,000

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, White House Office

I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act, H.R.4370, S.2220, S.1553), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act (S.2140, H.R.9474, S.1546). I have also supported disclosure of third-party litigation funding (e.g., H.R.1109 and S.3826). I have also supported limitations on foreign entities that represent a national security risk obtaining and enforcing U.S. patents (e.g., H.R.9142, the Prohibiting Adversarial Patents Act).

Client expense: Not reported · Firm income: $110,000

Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Patent & Trademark Office (PTO), SENATE, White House Office

Antitrust Legislation ---Oversight Pharmacy Benefit Managers Artificial Intelligence (AI) Bayh-Dole Act/Tech Transfer ---Bayh-Dole Act ---March-In Rights Compulsory Licensing ---28 U.S.C. 1498 - Patent and copyright cases Data Privacy ---H.R.8413: SECURE Data Act ---Implementation of BIOSECURE Act Drug Patenting ---H.R.3160/S.1553: PREVAIL Act ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---H.R.9142: Prohibiting Adversarial Patents Act of 2026 ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act of 2025 ---S.1546/H.R.3152: Patent Eligibility Restoration Act (PERA) ---S.2658: Medication Affordability and Patient Integrity Act ---S.3014: Ensuring Timely Access to Generics Act of 2025 ---Department of Commerce Patent Valuation Fee Proposal ---Patent Litigation Reform ---Patent Tax/fees ---PTAB Reform ---Restrictions on Intellectual Property Rights ---Section 101 Modernization Foreign Drug Data Protection Law ---Implementation of BIOSECURE Act Intellectual Property Enforcement ---China

Client expense: $2,360,000 · Firm income: Not reported

Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act H.R. 6089: Biomanufacturing Excellence Act of 2025 H.R. 9102: Biotech Investment National Security Act of 2026 (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement

Client expense: $7,360,000 · Firm income: Not reported

Intellectual Property/Patent enforcement at the International Trade Commission; Advancing America's Interests Act; Annual appropriations related to reforms on the way the International Trade Commission handles patent cases and encouraging transparency in third party litigation funding; H.R. 9142, Prohibiting Adversarial Patents Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. International Trade Commission (ITC)

Issues related to intellectual property legislation and regulation; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecting Our Courts from Foreign Manipulation Act

Client expense: Not reported · Firm income: $70,000

Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement

Client expense: $890,000 · Firm income: Not reported